Medical News Feed
German Drug Data (Deutsch)
Norwegian Drug Data (Norge)
Netherlands Drug Data (Nederlands)
Swedish Drug Data (Sverige)
Want to submit or suggest content for the epgonline.org YouTube Clinical channel?
Contact us here
epgonline.org is not responsible for content on any 3rd party website
Please register to access disease diagnosis, patient management, physician tools.
By viewing the content of this web page you are both confirming your status as a healthcare professional and agreeing to our terms of use.
| Drug class description : | 5HT1-agonists |
| Generic Name : | Almotriptan |
| Drug description : | White, circular, film-coated tablets with a blue printed A on one side. |
| Presentation : | Tablets, almotriptan 12.5mg (as almotriptan D,L-hydrogen malate). |
| Indications : | Acute treatment of the headache phase of migraine attacks with or without aura. |
| Adult Dosage : | Recommended dose, one tablet with or without food. A second dose may be taken if the symptoms reappear within 24 hours; there must be a minimum interval of two hours between the two doses. If a patient does not respond to the first dose a second dose should not be taken for the same attack. Maximum recommended dose, two tablets in 24 hours. Almogran should be taken with liquids after the onset of migraine-associated headache. It should not be used for migraine prophylaxis. |
| Child Dosage : | Not recommended. |
| Contra Indications : | Hypersensitivity to any component of the product. As with other 5HT receptor agonists, almotriptan should not be used in 1B/D patients with a history, signs or symptoms of ischaemic heart disease (myocardial infarction, angina pectoris, documented silent ischaemia, Prinzmetal's angina) or severe hypertension and uncontrolled mild or moderate hypertension. Patients with a previous cerebrovascular accident (CVA) or transient ischaemic attack (TIA). Peripheral vascular disease. Concomitant administration of almotriptan and lithium should be avoided. Concomitant administration with ergotamine, ergotamine derivatives (including methysergide) and other 5HT agonists is contraindicated. 1B/D Severe hepatic impairment. |
| Special Precautions : | For use only when there is a clear diagnosis of migraine. Should not be used to treat basilar, hemiplegic or ophthalmoplegic migraine. Exclude other potentially serious neurological conditions before treating patients with no previous diagnosis or migraine or patients with atypical symptoms. Do not treat patients who could have an undiagnosed coronary condition (eg, postmenopausal women, males over 40 and patients with other risk factors for coronary disease such as uncontrolled hypertension, hypercholesterolaemia, obesity, diabetes, smoking or a clear family history of cardiovascular disease) without prior evaluation of potential underlying cardiovascular disease. Known hypersensitivity to sulphonamides. Recommended that ergotamine should not be given for at least six hours following almotriptan administration; almotriptan should not be given for at least 24 hours following administration of an ergotamine-containing preparation. Severe renal impairment - maximum dose, moderate hepatic disease. May cause mild, transient increases in blood pressure - may be more pronounced in the elderly. Pregnancy, lactation. |
| Interactions : | Ergotamine. |
| Adverse Reactions : | Dizziness, somnolence, nausea, vomiting and fatigue. Less commonly, paraesthesia, diarrhoea, chest pain, dyspepsia, dry mouth, throat tightness, myalgia, headache, asthenia, palpitation, skeletal pain, tinnitus. |
| Manufacturer : | Almirall Prodesfarma |
Only registered users have access to the full EPG Online Knowledge Base including drug search tools, interactive disease Knowledge Centres via the EPG Knowledge Library - with clinical and evidence based physician and research tools, MiMedia (build your own clinical media collection with everything from key opinion leader essays to mode of action videos and other multi-media content), the EPG Survey panel, health news updates and much much more.
Already Registered?
Please log-in now using our member login box.
Not a member?
Don't worry, registration is quick and FREE! We welcome all Healthcare professionals, doctors, nurses and medical students.
Register today to have full access to a wealth of drug data, educational and evidence based interactive guides across all major therapeutic areas, disease management, and clinical tools.
As a practicing Healthcare professional, you can also opt-in to join our market research panel – www.epgsurvey.com – and get paid for sharing your expert clinical opinions!
REGISTER today it only takes a minute! and it's FREE
Having problems?
Use our forgotten password facility or email us at: contact@epgonline.org